Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme receives "complete response" letter for Clolar

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has issued a "complete response" letter for Genzyme's sNDA for use of Clolar (clofarabine) in previously untreated older adult patients with acute myeloid leukemia, the firm announced Oct. 6. FDA's Oncologic Drugs Advisory Committee voted in September that data from a randomized, controlled trial was necessary to establish safety and efficacy in the proposed adult AML indication (1"The Pink Sheet," Sept. 7, 2009). FDA's letter recommends Genzyme conduct such a trial. Drug sponsors seeking approval for elderly AML have argued that randomized trials are difficult to conduct in the setting, and Genzyme sought approval based on a single-arm trial. The company is already conducting a randomized, placebo-controlled Phase III trial of clofarabine plus cytarabine in relapsed and refractory AML patients over 55, with results expected in 2011. Genzyme plans to meet with FDA to discuss whether the additional study may satisfy regulatory requirements. Clolar is already approved for pediatric ALL

You may also be interested in...

No Regulatory Slack For Tough Supplemental Indications, Pazdur Tells ODAC

FDA may hold approval of supplemental indications to a higher standard of evidence than what can feasibly be obtained since the drugs are already available to treat patients in an off-label setting, FDA Office of Drug Oncology Products Director Richard Pazdur indicated at a Sept. 1 advisory committee meeting

Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation

Senate Appropriations Committee proposes $1.185bn to CFSAN and $2.19bn to CDER, both levels short of House appropriators passed in June. FDA requested $30.36m in user fees from monograph drugs but no amount was specified in Senate draft bill.

Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch

Along with Q2 results including reported net sales up 14.3% to $1.12bn, Perrigo announces overhaul of its supply chain expected to generate $100m to $300m in net cost savings and creation of women's health, skin care business units.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts